Extended access to fentanyl vapor self-administration leads to addiction-like behaviors in mice: Blood chemokine/cytokine levels as potential biomarkers
- PMID: 36683829
- PMCID: PMC9851134
- DOI: 10.1016/j.addicn.2022.100057
Extended access to fentanyl vapor self-administration leads to addiction-like behaviors in mice: Blood chemokine/cytokine levels as potential biomarkers
Abstract
Rodent models are useful for understanding the mechanisms that underlie opioid addiction, but most preclinical studies have focused on rewarding and consummatory aspects of opioids without components of dependence-induced escalation of drug taking or seeking. We characterized several opioid-related behaviors in mice using a model of vaporized fentanyl self-administration. Male and female C57BL/6J mice were assigned to short-access (ShA; 1 h, nondependent) or long-access (LgA; 6 h, dependent) fentanyl vapor self-administration and subsequently tested in a battery of behavioral tests, followed by blood collection during withdrawal. Compared with mice in the ShA group, mice in the LgA group escalated their fentanyl intake, were more motivated to work to obtain the drug, exhibited greater hyperalgesia, and exhibited greater signs of naloxone-precipitated withdrawal. Principal component analysis indicated the emergence of two independent behavioral constructs: "intake/motivation" and "hyperalgesia/punished seeking." In mice in the LgA condition only, "hyperalgesia/punished seeking" was associated with plasma levels of proinflammatory interleukin-17 (IL-17), chemokine (C-C motif) ligand 4 (CCL-4), and tumor necrosis factor α (TNF-α). Overall, the results suggest that extended access to opioids leads to addiction-like behavior, and some constructs that are associated with addiction-like behavior may be associated with levels of the proinflammatory cytokines/chemokines IL-17, TNF-α, and CCL-4 in blood.
Keywords: Addiction-like behavior; Extended access; Hyperalgesia; Operant self-administration; Opioid use disorder (OUD); Punishment; Substance use disorder (SUD).
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
References
-
- American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association Publishing, 2022. [Internet]. DSM-5-TR[cited 2022 Aug 9]. Available from https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890425787. - DOI
-
- Labor Unooda. World drug report 2021 (SET OF 5 BOOKLETS). S.l.: UNITED NA-TIONS; 2022.
-
- Koob GF, Neurobiology of opioid addiction: opponent process, hyperkatifeia, and negative reinforcement, Biol. Psychiatry 87 (1) (2020) 44–53 [Internet]Jan [cited 2021 Sep 30]Available from https://linkinghub.elsevier.com/retrieve/pii/S0006322319314350. - PubMed
-
- Carcoba LM, Contreras AE, Cepeda-Benito A, Meagher MW, Negative affect heightens opiate withdrawal-induced hyperalgesia in heroin dependent individuals, J. Addict. Dis 30 (3) (2011) 258–270 [Internet]Jul [cited 2020 Mar 16]Available from http://www.tandfonline.com/doi/abs/10.1080/10550887.2011.581985. - DOI - PMC - PubMed
-
- Higgins C, Smith BH, Matthews K, Evidence of opioid-induced hyperalgesia in clinical populations after chronic opioid exposure: a systematic review and meta-analysis, Br. J. Anaesth. 122 (6) (2019) e114–e126 [Internet]Jun [cited 2020 Jun 17]Available from https://linkinghub.elsevier.com/retrieve/pii/S0007091218307633. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources